However, EGFR mutated, and non-mutated cancer cells can concurrently exist in a considerable proportion of NSCLC, leading to the heterogeneity of NSCLC cells which results in a reduced response to gefitinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.